Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - Biocon/Viatris

Next Previous
Drug Profile

Bevacizumab biosimilar - Biocon/Viatris

Alternative Names: Abevmy; KRABEVA; Lextemy; MYL 1402O

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon
  • Developer Biocon; Viatris Inc
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Brain cancer; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Renal cell carcinoma

Most Recent Events

  • 10 Apr 2025 Registered for Cervical cancer (Recurrent, Metastatic disease) in USA (IV)
  • 10 Apr 2025 Registered for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 10 Apr 2025 Registered for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top